Shree Pacetronix

Why is Shree Pacetronix Ltd falling/rising?

As of 01-Sep, Shree Pacetronix Ltd's stock price is rising to Rs 140.80, driven by strong operational performance and increased promoter confidence, despite a year-to-date decline of 25.82%. The stock's rise reflects positive market sentiment and management efficiency, although it faces challenges like reduced delivery volume.

As of 01-Sep, Shree Pacetronix Ltd's stock price is rising, currently at Rs 140.80, reflecting a change of 2.05 (1.48%) upwards. This increase can be attributed to several factors. The stock has outperformed its sector by 2.07% today, indicating positive market sentiment. Additionally, the stock reached an intraday high of Rs 142.5, which is a 2.7% increase from the previous levels, suggesting strong buying interest at that point.<BR><BR>Moreover, the company exhibits high management efficiency with a return on capital employed (ROCE) of 24.31% and a low debt to EBITDA ratio of 0.51, indicating a strong ability to service its debt. The operating profit has also shown healthy growth, increasing at an annual rate of 38.74%. Despite the stock's year-to-date decline of 25.82% and a one-year return of -15.84%, the company's profits have surged by 214.6%, which reflects a significant improvement in profitability.<BR><BR>Furthermore, there is rising promoter confidence, as the promoters have increased their stake by 4.74% over the previous quarter, now holding 36.44% of the company. This increase in stake is often viewed as a positive signal regarding the company's future prospects.<BR><BR>However, it is important to note that the stock has faced challenges, including a significant drop in delivery volume, which fell by 54.59% against the 5-day average, and a consistent underperformance against benchmarks over the last three years. Despite these challenges, the current rise in stock price can be attributed to the positive factors mentioned, particularly the strong operational performance and increased promoter confidence.

Who are in the management team of Shree Pacetronix?

The management team of Shree Pacetronix includes Atul Kumar Sethi (Executive Director and Managing Director), Akash Sethi (Executive Director and Joint Managing Director), and four Independent Non-Executive Directors: Sushil Patni, Manali Tongia, Somya Chhabra, and Chandragupt Jain.

The management team of Shree Pacetronix includes the following individuals:<BR><BR>1. Atul Kumar Sethi - Executive Director, Managing Director, and Promoter<BR>2. Akash Sethi - Executive Director, Joint Managing Director, and Promoter<BR>3. Sushil Patni - Independent Non-Executive Director<BR>4. Manali Tongia - Independent Non-Executive Director<BR>5. Somya Chhabra - Independent Non-Executive Director<BR>6. Chandragupt Jain - Independent Non-Executive Director<BR><BR>If you need more specific information about their roles or contributions, feel free to ask!

What does Shree Pacetronix do?

Shree Pacetronix Ltd is a manufacturer and exporter of pacemakers in the healthcare sector, with a market cap of INR 52 Cr and recent net sales of 5 Cr and net profit of 1 Cr as of June 2026. The company has a P/E ratio of 16.00 and a return on equity of 17.63%.

Overview: <BR>Shree Pacetronix Ltd is a leading manufacturer and exporter of pacemakers, operating in the healthcare services industry within the micro-cap market.<BR><BR>History: <BR>Shree Pacetronix Ltd was incorporated in January 1988 as a Private Limited Company and converted into a Public Limited Company in 1993. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 5 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 52 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 16.00 <BR>Industry P/E: 112 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.05 <BR>Return on Equity: 17.63% <BR>Price to Book: 2.93 <BR><BR>Contact Details: <BR>Address: Plat No 15 Sector II, Industrial Area Pithampur Dhar Madhya Pradesh : 454775 <BR>Tel: 91-7292-411105 <BR>Email: info@pacetronix.com/pacetronix@hotm <BR>Website: http://www.pacetronix.com

Who are the peers of the Shree Pacetronix?

Shree Pacetronix's peers include Aspira Pathlab, Royal Sense, Amkay Products, KMS Medisurgi, N G Industries, Centenial Surgic, Bandaram Pharma, and Aakaar Medical. In terms of management risk, Shree Pacetronix is rated as Good, with varying growth and capital structures among its peers.

Peers: The peers of Shree Pacetronix are Aspira Pathlab, Royal Sense, Amkay Products, KMS Medisurgi, N G Industries, Centenial Surgic, Bandaram Pharma, and Aakaar Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense, Amkay Products, N G Industries, and Aakaar Medical, while Good management risk is found at Shree Pacetronix. Below Average management risk is seen at Aspira Pathlab, Centenial Surgic, and Bandaram Pharma. Growth is Excellent at Royal Sense and Bandaram Pharma, Good at Shree Pacetronix, Amkay Products, and Aakaar Medical, and Below Average at Aspira Pathlab, KMS Medisurgi, N G Industries, and Centenial Surgic. Average capital structure is noted at Aspira Pathlab and Centenial Surgic, while Good capital structure is found at Royal Sense, Shree Pacetronix, Amkay Products, KMS Medisurgi, N G Industries, and Aakaar Medical.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aspira Pathlab at 41.50%, while the lowest is Royal Sense at -62.36%. Shree Pacetronix has a 1-year return of -15.43%, which is higher than Royal Sense but lower than Aspira Pathlab. Additionally, KMS Medisurgi and N G Industries have negative six-month returns.

How big is Shree Pacetronix?

As of 31st August, Shree Pacetronix Ltd has a market capitalization of 52.00 Cr, with net sales of 21.19 Cr and a net profit of 3.24 Cr reported in the latest four quarters. The balance sheet for March 2025 shows shareholder's funds of 13.78 Cr and total assets of 22.58 Cr.

As of 31st August, Shree Pacetronix Ltd has a market capitalization of 52.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Shree Pacetronix reported net sales of 21.19 Cr and a net profit of 3.24 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 13.78 Cr and total assets of 22.58 Cr.

Which are the latest news on Shree Pacetronix?

Should I buy, sell or hold Shree Pacetronix Ltd?

When is the next results date for Shree Pacetronix Ltd?

The next results date for Shree Pacetronix Ltd is 13 August 2026.

The next results date for Shree Pacetronix Ltd is scheduled for 13 August 2026.

Are Shree Pacetronix Ltd latest results good or bad?

Shree Pacetronix Ltd's latest Q4 FY26 results show strong growth, with a net profit of ₹1.11 crores (up 146.67% year-on-year) and revenue of ₹5.37 crores (up 25.47% year-on-year). However, the company's significant quarterly volatility raises concerns about the sustainability of its earnings, suggesting investors should proceed with caution.

Shree Pacetronix Ltd's latest results for Q4 FY26 indicate a significant improvement compared to previous periods. The company reported a net profit of ₹1.11 crores, which is a remarkable 146.67% increase year-on-year from ₹0.45 crores in Q4 FY25. Revenue also saw healthy growth, reaching ₹5.37 crores, marking a 25.47% increase year-on-year and a 24.02% increase quarter-on-quarter. Additionally, the operating margin expanded dramatically to 30.54%, up from 9.93% in the previous quarter, indicating improved operational efficiency.<BR><BR>However, it's important to note that despite these strong headline figures, the company has exhibited extreme quarterly volatility in its performance. This inconsistency raises concerns about the sustainability of earnings and the predictability of the business, particularly in the specialized cardiac device manufacturing sector. <BR><BR>Overall, while the latest results appear good on the surface, the underlying volatility and past performance patterns suggest that investors should exercise caution and consider the potential risks involved.

Is Shree Pacetronix overvalued or undervalued?

As of November 24, 2025, Shree Pacetronix is considered undervalued with a PE ratio of 42.49 and a strong year-to-date return of 101.36%, significantly outperforming the Sensex, while trading at a more favorable valuation compared to peers like Poly Medicure and Blue Jet Health.

As of 24 November 2025, Shree Pacetronix has moved from a fair to a very attractive valuation grade. The company is currently considered undervalued. Key ratios include a PE ratio of 42.49, an EV to EBITDA of 23.84, and a ROCE of 18.04%. In comparison, peers such as Poly Medicure and Blue Jet Health show significantly higher PE ratios of 54.6 and 26.77, respectively, indicating that Shree Pacetronix is trading at a more favorable valuation relative to its peers.<BR><BR>Despite a recent decline in stock price, Shree Pacetronix has demonstrated strong performance with a year-to-date return of 101.36%, significantly outperforming the Sensex's return of 8.65% in the same period. This suggests that the market may not fully recognize the company's growth potential, reinforcing the view that it is undervalued in the current market environment.

How has been the historical performance of Shree Pacetronix?

Shree Pacetronix has experienced declining net sales and profitability, with net sales dropping from 22.04 crore in March 2024 to 16.80 crore in March 2025, and profit after tax falling from 3.36 crore to 0.75 crore in the same period. Despite this, total assets and liabilities increased, leading to a slight improvement in book value per share from 36.21 to 38.29.

Answer:<BR>The historical performance of Shree Pacetronix shows a fluctuating trend in net sales and profitability over the years. <BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Shree Pacetronix reported net sales of 16.80 crore, a decline from 22.04 crore in March 2024 and 20.26 crore in March 2023. The total operating income mirrored this trend, remaining at 16.80 crore in March 2025, down from 22.04 crore the previous year. The company's total expenditure, excluding depreciation, was 14.49 crore in March 2025, a decrease from 16.24 crore in March 2024. Operating profit, excluding other income, was 2.31 crore in March 2025, a significant drop from 5.80 crore in March 2024. Consequently, profit before tax also fell to 1.04 crore in March 2025 from 4.62 crore in March 2024, leading to a profit after tax of 0.75 crore, down from 3.36 crore the prior year. The earnings per share decreased to 2.08 in March 2025 from 9.33 in March 2024. On the balance sheet, total assets rose to 22.58 crore in March 2025, up from 21.33 crore in March 2024, while total liabilities increased to 22.58 crore from 21.33 crore. The book value per share adjusted to 38.29 in March 2025 from 36.21 in March 2024, indicating a slight improvement in shareholder value despite the decline in profitability.

Who are the top shareholders of the Shree Pacetronix?

The top shareholders of Shree Pacetronix include promoter Atul Kumar Sethi with 19.6%, public shareholder Bio-pace Technology Inc at 15.84%, and individual investors holding 45.8%. The promoter has a pledged holding of 14.78%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Shree Pacetronix include Atul Kumar Sethi, who is the promoter with the highest holding at 19.6%. The highest public shareholder is Bio-pace Technology Inc, holding 15.84%. Additionally, individual investors collectively hold 45.8% of the shares. The company also has a pledged promoter holding of 14.7768%, but there are currently no mutual funds or foreign institutional investors (FIIs) involved.

What is the technical trend for Shree Pacetronix?

As of May 12, 2025, Shree Pacetronix shows a mildly bearish trend due to mixed signals across timeframes, with weekly indicators suggesting mild bullishness while monthly indicators remain bearish.

As of 12 May 2025, the technical trend for Shree Pacetronix has changed from bearish to mildly bearish. The weekly MACD and Bollinger Bands indicate a mildly bullish stance, while the monthly indicators show bearish signals. The RSI on the weekly timeframe presents no signal, but is bullish on the monthly. Daily moving averages are mildly bearish, suggesting short-term weakness. Overall, the current technical stance is mildly bearish, driven primarily by the mixed signals across different timeframes, particularly the divergence between weekly and monthly indicators.

Has Shree Pacetronix declared dividend?

Yes, Shree Pacetronix Ltd has declared a 5% dividend, amounting to 0.4700 per share, with an ex-date of September 24, 2007. However, the total returns over various periods have shown significant volatility, with negative returns in shorter time frames and a notable positive return over three years.

Shree Pacetronix Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.4700<BR>- Ex-date: Sep-24-2007<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -33.86%, the dividend return was 0%, resulting in a total return of -33.86%.<BR><BR>For the 1-year period, the price return was -61.93%, the dividend return was 0%, leading to a total return of -61.93%.<BR><BR>Over the 2-year period, the price return was -51.24%, the dividend return was 0%, which resulted in a total return of -51.24%.<BR><BR>In the 3-year period, the price return was 279.15%, the dividend return was 0%, culminating in a total return of 279.15%.<BR><BR>For the 4-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Shree Pacetronix declared a dividend, the total returns over various periods show significant volatility, with a notable positive return over three years but negative returns in shorter time frames. The lack of dividend yield indicates that the dividends have not contributed to the overall returns in recent periods.